Skip to content

Tag: Myelin oligodendrocyte glycoprotein antibody associated disease

Explore our medication guides and pharmacology articles within this category.

What Is the New Treatment for MOGAD?: A Look at Emerging Therapies

3 min read
While over 90% of adults and children with MOGAD experience a full or near-full recovery after their first acute attack, no FDA-approved long-term preventative options exist. This has led to a major focus on research into **what is the new treatment for MOGAD** to prevent relapses and improve long-term outcomes.